Summary of 2019 Vetvicka Study in Journal of Nutrition and Health Sciences

Effects of Transfer Factor Supplementation on Immune Reactions in Mice (Vetvicka, 2019) – Study Summary

Background

Transfer factors are small immune signaling molecules originally identified in immune cell extracts, and more recently obtained from sources like cow colostrum and egg yolk. They are marketed as potent natural immunostimulatory supplements for supporting immune health. These colostrum-derived transfer factor products have become popular, yet their precise mechanisms of action and broad efficacy remain not fully defined. Companies often promote transfer factor supplements with general claims of “boosting the immune system,” even though traditional research on transfer factors focused on antigen-specific immunity. This gap in understanding provided the impetus for Vetvicka et al. (2019) to rigorously evaluate the immunological impact of a colostrum-based transfer factor and its combinations with other bioactive nutrients.

Objectives

The study had two main objectives: (1) to determine whether a standard oral colostrum-derived transfer factor supplement (as a non-specific immune enhancer) can significantly stimulate various immune responses in mice, and (2) to assess if adding other bioactive ingredients (such as polysaccharide immunomodulators or a whey-derived extract) to the transfer factor formula can enhance or synergize its immune-boosting effects. In essence, the researchers wanted to confirm general immune benefits of transfer factor and to find out if a modified “enhanced” formulation would yield superior immunological outcomes compared to transfer factor alone.

Methodology

Experimental Design: Female BALB/c mice (8 weeks old) were divided into groups and given one of several supplement treatments (donated by 4Life Research and Glanbia Nutritionals) orally each day:

• Tri-Factor (TF): a base colostrum-derived transfer factor supplement (standard formula).
  
• Transfer Factor Plus (TFP): an enhanced 4Life formula containing the transfer factor plus additional immune-active ingredients (e.g. herbal/polysaccharide components).
  
• TFP without TF: the enhanced formula’s additional ingredients without the transfer factor component (used to isolate the effects of the added bioactives alone).
  
• Wheymune: a proprietary whey protein–derived immunomodulator (from Glanbia).
  
• Tri-Factor + Wheymune: a combination of the colostrum transfer factor (Tri-Factor) together with the Wheymune supplement.
  

A control group (no supplementation) was included for baseline comparison. All supplements were administered once daily for 7 days (except in the antibody-response experiment, where supplementation continued for 21 days to cover the immunization schedule).

Measurements: After the treatment period, the mice’s immune function was evaluated through a battery of assays targeting both innate and adaptive immunity. Key outcomes measured included:

• Phagocytic activity of immune cells (the ability of blood monocytes and neutrophils to engulf foreign particles).
  
• Cytokine levels, specifically tumor necrosis factor-alpha (TNF-α) in serum (in vivo) and interleukin-2 (IL-2) production by isolated spleen cells (in vitro), as indicators of immune signaling.
  
• Antibody production against a test antigen (ovalbumin), measured by ELISA after immunizing the mice, to assess adaptive (humoral) immune response.
  
• Natural Killer cell activity, evaluated by a standard cytotoxicity assay using NK-sensitive YAC-1 tumor target cells, to gauge innate immune cytotoxic function.
  

All groups were compared to the control to determine if the supplements induced significant changes in these immune parameters. Appropriate statistical analyses (paired t-tests) were used to identify significant differences.

Results

After the supplementation period, all groups receiving transfer factor-based supplements showed enhanced immune responses compared to the unsupplemented controls, though the magnitude of improvement varied by formulation. The key findings for each measured outcome are summarized below:

• Phagocytic Activity: The colostrum transfer factor alone (Tri-Factor) significantly increased the phagocytic capacity of blood neutrophils and monocytes relative to control mice. In contrast, the full Transfer Factor Plus formula (TFP, which includes additional ingredients) did not show a significant effect on phagocytosis compared to control. Notably, the TFP formulation without its transfer factor component (i.e. only the added ingredients) stimulated phagocytosis to a degree comparable to Tri-Factor alone and significantly greater than the intact TFP supplement. Additionally, while Wheymune by itself had no appreciable impact on phagocytic activity, combining Wheymune with the Tri-Factor supplement yielded a synergistic enhancement of phagocytosis in immune cells.
  
• Cytokine Production (TNF-α and IL-2): All treated groups exhibited significantly elevated cytokine levels compared to controls. Serum TNF-α concentrations were higher in every supplement-fed group, with the most pronounced TNF-α increase observed in mice given the “TFP without TF” preparation (the additional ingredients alone). Moreover, combining the base transfer factor with the full plus formula (TF + TFP together) led to greater TNF-α production than either component on its own, indicating a synergistic effect; similarly, adding Tri-Factor to Wheymune substantially boosted TNF-α output over Wheymune alone. IL-2 secretion from cultured spleen cells was also significantly increased in all supplement groups. In fact, every transfer factor-containing regimen induced higher IL-2 levels relative to unsupplemented mice (consistent with an immunostimulatory effect), and there were no significant differences in IL-2 output among the various supplement formulations (all were effective to a similar extent). (As a reference, the IL-2 produced by supplements was lower than that induced by a potent mitogen like Concanavalin A, indicating that while transfer factor stimulates IL-2, it does so within a physiologically moderate range.)
  
• Antibody Response: The ability to mount an antigen-specific antibody response was improved in all supplemented groups. Mice that received any of the transfer factor-based supplements developed significantly higher titers of anti-ovalbumin antibodies than control mice when immunized with the antigen. Among the treatments, the most robust antibody responses were seen in two groups: those given the Transfer Factor Plus formulation without its transfer factor (suggesting the additional ingredients alone strongly enhanced humoral immunity), and those given the combination of Tri-Factor + Wheymune. Even the standard transfer factor and full TFP supplement showed elevated antibody levels versus control, but the above two formulations were standout performers in boosting antibody production.
  
• NK Cell Activity: Natural killer cell cytotoxicity against tumor cells was markedly increased in all mice that received transfer factor supplements compared to controls. This indicates an overall enhancement of innate immune surveillance. The highest NK cell killing activity was observed in the group that received the TFP additional ingredients without transfer factor, mirroring the trends seen with TNF and antibody results. Importantly, supplementation with Tri-Factor significantly augmented the NK cell response to Wheymune, meaning the combination of the colostrum transfer factor with the whey-based immunomodulator produced greater NK cytotoxic activity than Wheymune alone. All other groups (including Tri-Factor by itself and TFP) also showed elevated NK activity relative to untreated mice, underscoring the immune-boosting capacity of these supplements in stimulating cell-mediated cytotoxic defense.
  

In summary, the 7-day transfer factor supplementation led to broad improvements in immune function, as evidenced by enhanced phagocyte activity, higher cytokine production, increased antibody generation, and stronger NK cell cytotoxicity in treated mice. The data also revealed that combinatorial formulations can influence the magnitude of the response – in some cases yielding synergy (e.g. TF + Wheymune) or unexpected outcomes like the non-transfer factor components performing as well as the complete supplement.

Conclusions

This 2019 study provides clear evidence that colostrum-derived transfer factor acts as an effective natural immunomodulator, capable of significantly stimulating both innate and adaptive immune responses in a non-antigen-specific manner. The first objective was affirmatively answered: even a regular oral transfer factor supplement produced measurable immune enhancements across a wide spectrum of immune functions (phagocytes, cytokines, antibodies, NK cells) in the animal model. These findings support some of the health claims that transfer factor-based nutritional supplements can bolster immune system activity.

The second objective – optimizing the supplement formula by adding other bioactive components – yielded mixed but insightful results. On one hand, certain combinations improved efficacy: for example, adding the colostrum transfer factor to the Wheymune whey extract clearly potentiated the immune-stimulating effects of the latter. On the other hand, the study found that the proprietary Transfer Factor Plus blend did not always outperform the simpler formulations; intriguingly, the mixture of additional ingredients (minus the transfer factor itself) often performed equal or superior to the full transfer factor plus formula in these tests. This suggests that some components in the mixture may independently boost immunity or that there may be an optimal dosing balance that was disrupted in the combined product.

In conclusion, colostrum-derived transfer factor supplementation demonstrated broad immunological benefits in mice, reinforcing its potential value for immune health. However, the efficacy of enhanced multi-ingredient formulations requires further clarification. The authors note that more experiments are underway to determine the ideal composition and synergy of transfer factor with other immunomodulators. Fine-tuning such formulations could maximize immune benefits, informing the development of improved nutritional immune supplements in the future.

References

1. Levin AS, Spitler LE, Stites DP, Fundenberg HH (1970) Wiscott Aldrich syndrome, a genetically determined cellular immunologic deficiency clinical and laboratory responses to therapy with transfer factor. Proc Natl Acad Sci USA 67: 821-8.
2. Fudenberg HH, Pizza G (1993) Transfer factor 1993: new frontiers. Prog Drug Res 42: 309-400.
3. Kirkpatrick CH, Burger DR, Lawrence HS (1983) Immunobiology of Transfer Factor. Academic Press, New York, USA.
4. Lawrence HS (1955) The transfer in humans of delayed skin sensitivity to streptococcal M substance and to tuberculin with disrupted leucocytes. J Clin Investig
   34: 219-30.
5. Wilson GB, Poindexter C, Fort JF, Ludden KD (1988) De novo initiation of specific cell-mediated immune responsiveness in chicken by transfer factor (specific
   immunity inducer) obtained from bovine colostrum and milk. Acta Virol 32: 6-18.
6. Radosevich JK, Scott GH, Olson GB (1985) Delayed-type hypersensitivity responses induced by bovine colostral components. Am J Vet Res 46: 875-8.
7. Wang JF, Park AJ, Rendini RN, Levis WR (2017) Lawrence transfer factor: Transference of specific immune memory by dialyzable leukocyte extract from a CF8+
   T cell line. J Drugs Dermatol 16: 1198-206.
8. Krishnaveni M (2013) A review on transfer factor an immune modulator. Drug Invent Today 5: 153-6.
9. Vetvicka V, Holub M, Kovaru H, Siman P, Kovaru F (1988) Alpha-fetoprotein and phagocytosis in athymic nude mice. Immunol Lett 19: 95-88.
10. Vetvicka V, Vetvickova J (2010) β1,3-Glucan: Silver bullet of hot air? Open Glycoscience 3: 1-6.
11. Zajicova A, Javorkova E, Trosan P, Chudickova M, Krulova M, et al. (2014) A low-molecular-weight dialyzable leukocyte extract selectively enhances development of CD4 (+)RORgamma(+) T cells and IL-17 production. Fol Biol (Praha) 60: 253-60.
12. Xu YP, Zou WM, Zhan XJ, Yang SH, Xie DZ, et al. (2006) Preparation and determination of immunological activities of anti-HBV egg yolk extraction. Cell
    Mol Immunol 3: 67-71.
13. Zhou J, Kong C, Yuan Z, Luo J, Ma RA, et al. (2013) Preparation, characterization, and determination of immunological activities of transfer factor specific to
    human sperm antigen. Biomed Res Int 2013: 126923.
14. Fabre RA, Perez TM, Aguilar LD, Rangel MJ, Estrada-Garcia I, et al. (2004) Transfer factors as immunoimmunotherapy and supplement of chemotherapy in
    experimental pulmonary tuberculosis. Clin Exp Immunol 136: 215-23.
15. Raise E, Guerra L, Viza D, Pizza G, De Vinci C, et al. (1996) Preliminary results in HIV-1-infected patients treated with transfer factor (TF) and zidovudine
    (ZDV). Biotherapy 9: 49-54.
16. Miller LL, Spitler LE, Allen RE, Minor DR (1988) A randomized, double-blind, placebo-controlled trial of transfer factor as adjuvant therapy for malignant
    melanoma. Cancer 61: 1543-9.
17. Pineda B, Estrada-Parra S, Pedraza-Medina B, Rodriguez-Ropon A, Perez R, et al. (2005) Interstitial transfer factor as adjuvant immunotherapy for experimental glioma. J Exp Clin Cancer Res 24: 575-83.
18. Kirkpatrick CH, Hamad AR, Morton LC (1995) Murine transfer factors: dose- response relationships and routes of administration. Cell Immunol 164: 203-6.
19. Vetvicka V, Fornusek L, Kopecek J, Kamínková J, Kaspárek L, et al. (1982) Phagocytosis of human blood leukocytes: A simple micromethod. Immunol Lett
    5: 97-100.